HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gillette used no animals for cosmetic safety validations in 1994 -- company report.

This article was originally published in The Rose Sheet

Executive Summary

GILLETTE 1994 COSMETICS SAFETY VALIDATION "MILESTONE": NO ANIMALS were used in validation tests for the 12-month period ending Sept. 30, 1994, according to the company's "1994 Report on Research with Laboratory Animals." Safety testing for cosmetic ingredients and finished cosmetic products in 1994 represented a "significant milestone" for Gillette, the company said. "In a year that marked the introduction of five new cosmetic and toiletry products," the report points out, "no research animal tests were used to validate the safety of Gillette cosmetic products." New product formulations introduced in 1994 include Soft & Dri, Dry Idea and Natrelt deodorants/antiperspirants; White Rain Exotics hair care; and a Jafra AHA skin care product.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel